| |
|
|
|
|
|
|
|||
|
Prepublished online as a Blood First Edition Paper on March 6, 2003; DOI 10.1182/blood-2002-10-3245.
Blood, 1 July 2003, Vol. 102, No. 1, pp. 142-145
Functional p85
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract |
|---|
|
|
|---|
regulatory subunit, fetal erythropoiesis was reportedly unaffected. Given the discrepancies between these studies, we performed a more detailed in vivo analysis of class IA PI-3 kinasedeficient embryos. Day-14.5 p85
-/- embryos are pale with a marked reduction of mature erythrocytes in their peripheral blood. Further, the absolute number and frequency of both early (erythroid burst-forming unit [BFU-E]) and late erythroid progenitors (erythroid colony-forming unit [CFU-E]) are reduced in p85
-/- fetal livers compared with wild-type controls, which is associated with reduced proliferation. Taken together, these data establish an important role for p85
and class IA PI-3 kinase in regulating the development of both early and late erythroid progenitors in fetal liver. (Blood. 2003;102:142-145) | Introduction |
|---|
|
|
|---|
regulatory subunit of this kinase.11,12 Although p85
-/- mice die shortly after birth secondary to hepatic necrosis and chylous ascites,12 we used p85
-/- embryos to investigate the effect of p85
deficiency on fetal liver erythropoiesis in vivo. | Study design |
|---|
|
|
|---|
p85
+/- mice (129/SV x C57BL/6) were obtained from Dr Lewis Cantley at Harvard University (Boston, MA). Studies were conducted with a protocol approved by the Indiana University Animal Care and Use Committee. The p85
allele was genotyped by polymerase chain reaction (PCR) as previously described.11,12 p85
+/- mice were mated to produce day-14.5 p85
-/- and p85
+/+ embryos. Fetal liver cells were isolated as previously described.13 Single cell suspensions were prepared by pushing the hepatic tissues through a 23-gauge needle.
Peripheral blood analysis and fetal liver erythropoiesis
Embryonic blood was obtained from day-14.5 fetal hearts for peripheral smears, and fetal liver touch preps were performed as previously described14 and stained with Wright-Giemsa (Dade Behring, Newark, DE). Photomicrographs of peripheral smears and touch preps were taken with an Olympus DP11 microscope (Melville, NY).
Colony assays
Recombinant KitL and Epo were obtained from Peprotech (Rocky Hill, NJ) and Amgen (Thousand Oaks, CA), respectively. Erythroid burst-forming unit (BFU-E) and erythroid colony-forming unit (CFU-E) assays were performed exactly as previously described.15
c-kit+ cell isolation
Fetal liver cells were incubated with 1 µg phycoerythrin (PE)conjugated c-kit monoclonal antibody (Pharmingen, San Diego, CA) per 106 cells, placed on ice for 20 minutes, pelleted, washed, and resuspended in phosphate-buffered saline (PBS). C-kit+ cells were purified by immunomagnetic bead enrichment as previously described.15
Apoptosis and proliferation assays
c-kit+ fetal liver cells were stained with fluorescein isothiocyanate (FITC)annexin V (Pharmingen) and propidium iodide (Sigma, St Louis, MO) exactly per manufacturer's protocol followed by flow cytometric analysis as previously described.16 For thymidine incorporation assays, 10 000 c-kit+ fetal liver cells were plated in 96-well plates in 5% fetal calf serum (BioWhittaker, Walkersville, MD) with Epo and KitL or no growth factors. After 48 hours in culture, cells were pulsed with tritiated thymidine (New Life Sciences, Boston, MA) for 16 to 24 hours and harvested on glass fiber filters, and
emission was measured.
| Results and discussion |
|---|
|
|
|---|
deficiency on fetal liver erythropoiesis, p85
+/- mice were intercrossed, and day-14.5 embryos were harvested for analysis. Day-14.5 p85
-/- embryos were pale compared with wild-type controls (Figure 1A) and demonstrated a marked reduction in the percentage of mature erythrocytes in their peripheral blood smears (Figure 1B). Most of the circulating cells in the p85
-/- embryos were nucleated megaloblasts or megalocytes (79% ± 5% versus 26% ± 8% for wild-type controls, n = 7, P < .05). In contrast, in wild-type peripheral blood, 80% to 90% of circulating cells were enucleated, mature red blood cells, or macrocytes, whereas the remaining cells were yolk sacderived megaloblasts (Figure 1B). This pattern was also demonstrated in day-14.5 fetal liver touch preps. Although there was a continuum of erythropoiesis in wild-type fetal liver, a predominance of nucleated erythroid precursors was present in p85
-/- fetal livers (Figure 1C).
|
We next assayed for early (BFU-E) and late (CFU-E) erythroid progenitors in wild-type and p85
-/- fetal livers. A marked reduction in the total number of BFU-E and CFU-E progenitors was observed in p85
-/- fetal livers compared with wild-type controls (Figure 1D). The reduction in BFU-Es and CFU-Es in p85
-/- fetal livers could be secondary to p85
deficiency in hematopoietic progenitors or alternatively a defect in the p85
-/- microenvironment. To directly test the effect of p85
deficiency on erythroid colony formation independent of the effects of the microenvironment, we performed BFU-E and CFU-E assays with equal numbers of sorted wild-type and p85
-/- c-kit+ cells, which are enriched for hematopoietic progenitors. A marked reduction in the frequency of both BFU-Es and CFU-Es was observed in c-kit+ cells isolated from day-14.5 p85
-/- fetal livers compared with wild-type controls (Figure 1E). Interestingly, the reduction in CFU-E frequency observed in p85
-/- c-kit+ cells was significantly greater when cells were stimulated with both KitL and Epo in combination compared with Epo alone (Figure 1E). Collectively, these results argue that an intrinsic p85
-/- hematopoietic progenitor cell defect contributes in part to the reduction of erythroid progenitors in day-14.5 p85
-/- fetal livers in vivo and the lack of mature erythrocytes in the peripheral blood of these affected fetuses.
Because these data establish a previously unrecognized role for p85
in regulating fetal erythropoiesis in vivo, we next tested whether the p85
-/- erythroid phenotype could be linked to either a decrease in proliferation and/or survival of hematopoietic progenitors. Prior studies argue that activation of the PI-3 kinase/Akt pathway by either Epo or KitL promotes the survival of erythroid progenitors.1,6,8,17 To test this hypothesis in vivo, we compared the percentage of both freshly isolated c-kit+ cells (a marker for early erythroid progenitors) or ter119+ cells (a marker for late erythroid progenitors) undergoing apoptosis harvested from wild-type and p85
-/- day-14.5 fetal livers. Cells were stained with annexin to identify apoptotic cells. No differences in apoptosis in either c-kit+ or ter119+ cells isolated from the 2 experimental genotypes were observed (Figure 2A). These data are consistent with 2 recent reports which show that p85
-/- mast cells do not have an increase in apoptosis in response to KitL compared with wild-type controls.18,19
|
We next tested whether p85
deficiency would alter the proliferation of c-kit+ progenitor cells in response to either KitL or Epo alone or in combination. Remarkably, p85
-/- c-kit+ cells displayed a 40% to 50% reduction in proliferation in response to KitL alone or KitL in combination with Epo compared with wild-type cells (Figure 2B). Such a proliferative defect would account for the diminished number of erythroid progenitors measured in the day-14.5 p85
-/- embryos. This finding would explain why knock-in mice harboring a mutation in the p85
binding domain of the c-kit receptor are not anemic as adult animals,20 whereas we note an erythropoietic defect in p85
-/- fetal livers. It is well known that rates of hematopoietic progenitor proliferation are approximately 2-fold higher in fetal liver compared with adult bone marrow under normal homeostatic conditions.21 Thus, a defect in basal and stimulated progenitor proliferation would affect fetal liver more than adult hematopoiesis. Further, other hematopoietic growth factors or integrins may act in synergy with KitL to transmit signals via class IA PI-3 kinase to augment the proliferation of erythroid progenitors. This situation would result in a more anemic phenotype in p85
-/- animals compared with mice containing only a mutation in the p85
binding site of the c-kit receptor. Finally, p85
-/- c-kit+ cells stimulated with Epo alone demonstrated only a 10% reduction in proliferation compared with wild-type cells (Figure 2B). This finding is consistent with the observation that mutant mice harboring an Epo receptor, which lacks the p85
binding site, are viable with relatively normal adult erythropoiesis.22 This observation is also consistent with our clonogenic data, which showed that p85
-/- c-kit+ cells had only a minor decrease in CFU-E formation in response to Epo alone (Figure 1E).
Thus, these studies clearly establish and clarify a role for p85
and class IA PI-3 kinase in regulating normal fetal erythropoiesis in vivo at least in part by promoting the proliferation of hematopoietic progenitors via signaling through the KitL/c-kit pathway. Our studies did not find a role for p85
in controlling the survival of c-kit+ cells in vivo. However, Akt activation in p85
-/- c-kit+ cells in response to either Epo or KitL was reduced by only 30% to 40% compared with wild-type controls (data not shown), which is consistent with previous studies using other primary p85
-/- cell lines stimulated with different growth factors.11,12,18,19,23 The retention of a significant amount of Akt activity in our p85
-/- cells may explain the differences in our results and previous in vitro studies using pharmacologic inhibitors of PI-3 kinase. Future studies designed to further reduce class IA PI-3 kinase activity in vivo in genetically engineered animal models will clarify the role of this kinase in regulating both fetal and adult erythropoiesis.
| Acknowledgements |
|---|
+/- mice, Marsha Hippensteel for exceptional administrative support, and Drs L. Haneline and D. Clapp (Indiana University) for many valuable discussions and thoughtful review of the manuscript.
| Footnotes |
|---|
Prepublished online as Blood First Edition Paper, March 6, 2003; DOI 10.1182/blood-2002-10-3245.
Supported by grants 1 KO8 CA096579
[GenBank]
-01 (D.A.I.) and R01HL63169 (M.C.Y.) from the National Institutes of Health and by grant P30 DK49218 (D.A.I.) from the National Institute of Diabetes and Digestive and Kidney Diseases. H.H. is a Howard Hughes Medical Institute Medical Student Research Training Fellow. D.A.I. is a recipient of a Basil O'Connor Award from the March of Dimes (5-FY02-254).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: David A. Ingram, Indiana University School of Medicine, Herman B. Wells Center for Pediatric Research, 1044 W Walnut St, R4/470, Indianapolis, IN 46202; e-mail: dingram{at}iupui.edu.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y. Zhang, E. Diaz-Flores, G. Li, Z. Wang, Z. Kang, E. Haviernikova, S. Rowe, C.-K. Qu, W. Tse, K. M. Shannon, et al. Abnormal hematopoiesis in Gab2 mutant mice Blood, July 1, 2007; 110(1): 116 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Bakker, T. B. van Dijk, M. Parren-van Amelsvoort, A. Kolbus, K. Yamamoto, P. Steinlein, R. G. W. Verhaak, T. W. Mak, H. Beug, B. Lowenberg, et al. Differential Regulation of Foxo3a Target Genes in Erythropoiesis Mol. Cell. Biol., May 15, 2007; 27(10): 3839 - 3854. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Bone and M. J. Welham Phosphoinositide 3-kinase signalling regulates early development and developmental haemopoiesis J. Cell Sci., May 15, 2007; 120(10): 1752 - 1762. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. F. Khalaf, F.-C. Yang, S. Chen, H. White, W. Bessler, D. A. Ingram, and D. W. Clapp K-ras Is Critical for Modulating Multiple c-kit-Mediated Cellular Functions in Wild-Type and Nf1+/- Mast Cells J. Immunol., February 15, 2007; 178(4): 2527 - 2534. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ghaffari, C. Kitidis, W. Zhao, D. Marinkovic, M. D. Fleming, B. Luo, J. Marszalek, and H. F. Lodish AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation Blood, March 1, 2006; 107(5): 1888 - 1891. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Haneline, H. White, F.-C. Yang, S. Chen, C. Orschell, R. Kapur, and D. A. Ingram Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo Blood, February 15, 2006; 107(4): 1375 - 1382. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhao, C. Kitidis, M. D. Fleming, H. F. Lodish, and S. Ghaffari Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway Blood, February 1, 2006; 107(3): 907 - 915. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Sanz, M. S. Tallman, and F. Lo-Coco Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia Oncologist, November 1, 2005; 10(10): 806 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tachibana, N. Jones, D. J. Dumont, M. C. Puri, and A. Bernstein Selective Role of a Distinct Tyrosine Residue on Tie2 in Heart Development and Early Hematopoiesis Mol. Cell. Biol., June 1, 2005; 25(11): 4693 - 4702. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. F. Khalaf, H. White, M. J. Wenning, A. Orazi, R. Kapur, and D. A. Ingram K-Ras is essential for normal fetal liver erythropoiesis Blood, May 1, 2005; 105(9): 3538 - 3541. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Weiss New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications Oncologist, December 1, 2003; 8(90003): 18 - 29. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||